Get alerts:Global net revenue totaled $84.1 million in the second quarter, including $75.2 million in toxin revenue and $8.9 million from injectable hyaluronic acid gels. Portfolio adoption and market conditions“The second quarter represents a meaningful inflection point for Evolus,” President and Chief Executive Officer David Moatazedi said. Moatazedi said Evolus estimates the U.S. neurotoxin market grew at a faster-than-expected mid-single-digit rate during the quarter. Jeuveau and Nuceiva posted double-digit toxin growth in the United States and international markets, while Evolysse revenue increased by more than $2 million sequentially. Profhilo agreement expands skin-quality strategyDuring the quarter, Evolus announced an exclusive agreement with IBSA to develop and commercialize Profhilo in the United States.